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A B S T R A C T
Cisplatin-induced ototoxicity remains a primary dose-limiting adverse eﬀect of this highly eﬀective anticancer
drug. The clinical utility of cisplatin could be enhanced if the signaling pathways that regulate the toxic side-
eﬀects are delineated. In previous studies, we reported cisplatin-induced nitration of cochlear proteins and
provided the ﬁrst evidence for nitration and downregulation of cochlear LIM domain only 4 (LMO4) in cisplatin
ototoxicity. Here, we extend these ﬁndings to deﬁne the critical role of nitrative stress in cisplatin-induced
downregulation of LMO4 and its consequent ototoxic eﬀects in UBOC1 cell cultures derived from sensory
epithelial cells of the inner ear and in CBA/J mice. Cisplatin treatment increased the levels of nitrotyrosine and
active caspase 3 in UBOC1 cells, which was detected by immunocytochemical and ﬂow cytometry analysis,
respectively. The cisplatin-induced nitrative stress and apoptosis were attenuated by co-treatment with SRI110,
a peroxynitrite decomposition catalyst (PNDC), which also attenuated the cisplatin-induced downregulation of
LMO4 in a dose-dependent manner. Furthermore, transient overexpression of LMO4 in UBOC1 cells prevented
cisplatin-induced cytotoxicity while repression of LMO4 exacerbated cisplatin-induced cell death, indicating a
direct link between LMO4 protein levels and cisplatin ototoxicity. Finally, auditory brainstem responses (ABR)
recorded from CBA/J mice indicated that co-treatment with SRI110 mitigated cisplatin-induced hearing loss.
Together, these results suggest that cisplatin-induced nitrative stress leads to a decrease in the levels of LMO4,
downregulation of LMO4 is a critical determinant in cisplatin-induced ototoxicity, and targeting peroxynitrite
could be a promising strategy for mitigating cisplatin-induced hearing loss.
1. Introduction
Cisplatin, a ﬁrst-generation platinum-based anti-neoplastic drug, is
used to treat cancers of the bladder, cervix, lung (non-small cell), ovary,
head & neck (squamous cell), testicle, and malignant mesothelioma.
According to the National Cancer Institute, 10–20% of all cancer
patients are prescribed cisplatin or its analogues. Cisplatin arrests cell
division to prevent tumor growth and induces programmed cell death
to reduce tumor size. However, cisplatin-induced apoptosis is not
restricted to tumor cells but extends to susceptible cells, such as the
outer hair cells in the cochlea. Therefore, ototoxicity is a major side-
eﬀect of cisplatin, which signiﬁcantly aﬀects the quality of life in cancer
survivors and has devastating consequences in children because it
aﬀects their speech and language development, education, and social
integration [1,2]. Although progress has been made in delineating the
mechanisms underlying cisplatin-induced ototoxicity [3–7], the signal-
ing pathways that facilitate cochlear apoptosis are yet to be fully
characterized. Thus, we do not yet have a comprehensive solution to
this important problem.
Among the cochlear cell death mechanisms reported so far,
oxidative stress is considered to play a causal role in cisplatin
ototoxicity [3,8] as cisplatin activates the enzyme NOX3, which
increases the production of superoxide radicals in the inner ear [9].
In addition, the activation of iNOS pathway and the generation of nitric
oxide have been detected in cisplatin ototoxicity [10,11]. Although
antioxidants are employed to prevent cisplatin ototoxicity they do not
provide a comprehensive solution as many of them interfere with the
anticancer activity of cisplatin. Hence, there is a need to identify
alternative downstream targets for intervention. We reported cisplatin-
induced increase in the nitration of proteins in the cochlear sensory
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epithelium [12] and detected a strong correlation between cochlear
protein nitration and cisplatin-induced hearing loss. Nitrative stress is
emerging as an important factor in acquired hearing loss as increased
levels of nitrotyrosine have been detected in several inner ear pathol-
ogies and associated with pathways related to the cochlear stress
response [13–18]. Targeting nitrative stress appears to be a plausible
strategy to prevent cisplatin-induced ototoxicity because co-treatment
with a PNDC did not interfere with the anticancer activity of paclitaxel
[19].
Our studies identiﬁed the nitration of cochlear LMO4 in cisplatin
ototoxicity [4]. As a molecular adaptor for protein-protein interactions,
LMO4 forms transcriptional complexes and thereby regulates cell
survival and cell death [20–23]. LMO4 plays an important role in the
development of the inner ear [24] and its downstream target STAT3 is
also implicated in cisplatin-ototoxicity [25–27]. We co-localized LMO4
and nitrotyrosine in the outer hair cells, which are primary targets of
cisplatin-induced ototoxicity [4]. Protein nitration can modulate phos-
phorylation cascades, alter protein function, and facilitate proteolytic
degradation of nitrated proteins [28–34]. Consistent with these
reports, cisplatin-induced nitration of LMO4 was associated with a
signiﬁcant decrease in its protein levels, not only in the auditory cells,
but in the renal and neuronal cells, which are also susceptible to the
toxic side-eﬀects of cisplatin [35]. Repression of LMO4 has been
reported to facilitate cellular apoptosis in other models [36,37].
Our objective, in this study, is to validate and extend the previous
correlational observations by clarifying the critical link between
cisplatin-induced nitrative stress, downregulation of LMO4, and oto-
toxicity. Based on our studies and other reports, we hypothesized that
downregulation of LMO4 by cisplatin-induced nitrative stress compro-
mises the anti-apoptotic machinery to facilitate ototoxicity. We objec-
tively tested our hypothesis by employing two approaches: 1) using a
PNDC to selectively inhibit nitrative stress and 2) genetically manip-
ulating the expression of LMO4 in sensory epithelial cells of the inner
ear.
2. Materials and methods
2.1. Animals
Six-week-old male CBA/J mice were purchased from Jackson
Laboratories (Jackson Laboratories, Bar Harbor, ME). All animals
were housed at the Laboratory Animal Facility of Wayne State
University and maintained in a temperature-controlled room with a
12-h light/dark cycle and allowed free access to food and water. Every
eﬀort was made to minimize pain and discomfort and all animals were
handled and treated according to guidelines established by the
National Institutes of Health and the Institutional Animal Care and
Use Committee (# A 04-07-14).
2.2. Cell culture
UBOC1 cells derived from the mouse organ of Corti were provided
by Dr. Mathew C Holley (University of Sheﬃeld, UK). The cells were
cultured in minimum essential medium (GlutaMAX, catalog no.
41090-036, Thermo Fisher Scientiﬁc, Rockford, IL) with 10% fetal
bovine serum (Gibco BRL, Gaithersburg, MD) and incubated in a
humidiﬁed atmosphere containing 10% CO2. For propagation the cells
were initially cultured in a medium containing 50 U/ml γ-interferon
(catalog no. 315-05, PeproTech, Rocky Hill, NJ, USA) and to facilitate
diﬀerentiation the cells were cultured for a week at 37 °C without γ-
interferon [38,39]. Fully diﬀerentiated cells were used for genetic
manipulation, drug treatment, and biochemical analyses. The expres-
sion of myosin VIIa was tested to verify diﬀerentiation.
2.3. Drug treatment
All chemicals and reagents including cisplatin (P4394) were
purchased from Sigma-Aldrich (St. Louis, MO, USA), unless noted
otherwise. UBOC1 cells were treated with 5 or 10 µm of cisplatin mixed
with culture medium for 24 h. SRI110, a manganese(III) bis(hydrox-
yphenyl)dipyrromethene catalyst, was synthesized as reported pre-
viously [19]. SRI110 (50 µm) was mixed with the culture medium, and
the cells were exposed to the drug 1 h prior to cisplatin treatment. In
mice, veterinary-grade cisplatin (Pharmachemie B.V., Haarlem,
Netherlands) was administered at 3 mg/kg body weight for 5 days
[41] by slow intraperitoneal infusion at the concentration of 1 mg/ml
in sterile saline (0.9%). Control animals were infused with an equal
volume of saline. SRI110 (10 mg/kg) was mixed with Nutella and
administered orally 1 h prior to cisplatin treatment on all 5 days. All
animals were hydrated daily with 10 ml/kg subcutaneous injection of
saline until they were sacriﬁced.
2.4. Protein extraction
The cells were homogenized in radio-immunoprecipitation assay
buﬀer supplemented with 5 mM EDTA, phosphatase, and protease
inhibitors (Thermo Fisher Scientiﬁc, Rockford, IL). The homogenate
was extracted on ice for 45 min and centrifuged at 14,000×g for
10 min. Protein concentration of the supernatant was determined by
Bradford assay [40].
2.5. Immunoblotting
Protein extracts were separated on 4–20% Mini-Protean TGX gel
(456-1093, Bio-Rad Laboratories, Inc., Hercules, CA), transferred to
polyvinylidene diﬂuoride membranes, blocked with 5% fat-free milk in
tris-buﬀered saline containing 0.05% Tween 20 (Sigma-Aldrich) and
probed with antibodies using chemiluminescence detection (34076,
Thermo Fisher Scientiﬁc, Rockford, IL). The FluorChem E imaging
system (ProteinSimple, Santa Clara, CA) was used to visualize bands,
which were quantiﬁed using NIH ImageJ software. Background
corrected bands were normalized against actin [4].
2.6. Immunocytochemistry
UBOC1 Cells were plated on two-well chamber slides (Nunc Lab-
Tek II Chamber Slide system, 154461, Fisher Scientiﬁc, Pittsburgh, PA,
USA) and treated with 10 µm cisplatin for 24 h. The cells were ﬁxed,
permeabilized, and blocked as described previously [35]. Then the cells
were incubated with anti-nitrotyrosine, anti-myosin VIIa (catalog no.
sc-32757, sc-74516, Santa Cruz Biotechnology Inc., Santa Cruz, CA) or
anti-LMO4 (catalog no. ab39383, Abcam, Cambridge, MA) followed by
incubation with Alexa Fluor 568 donkey anti-mouse or Alexa Fluor 647
goat anti-rabbit secondary antibody (catalog no. A10037 or A21244,
Life Technologies, Carlsbad, CA) and ﬂuorescein phalloidin (catalog no.
F432, Life Technologies). ProLong Gold antifade reagent containing
DAPI (catalog no. P36935, Life Technologies) was used for mounting
the cells and Carl Zeiss Laser Scanning Systems (Zeiss LSM 780, Jena,
Germany) was used to capture the images of the stained cells.
2.7. Silencing of LMO4
UBOC1 cells were transfected with a combination of four siRNAs
(Qiagen, Valencia, CA): Hs_LMO4_8 (catalog no. SI04270966),
CGGCACGTCCTGTTACACCAA; Hs_LMO4_9 (catalog no.
SI04312973), CCGCCTCTCGCAATATTGCAA; HsLMO4_6 (catalog
no. SI03185777), CCCGGGAGATCGGTTTCACTA; Hs_LMO4_7 (cata-
log no. SI04151231), AGGAAACGTGTTTCAATCAAA in Opti-MEM
reduced serum medium (Invitrogen, catalog no. 31985) using
Oligofectamine (Invitrogen, catalog no. 12252-011). AllStars Negative
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Control siRNA (Qiagen, catalog no. 1027280),
CAGGGTATCGACGATTACAAA, was used as a negative control. The
cells were incubated for 24 h for silencing the gene and then treated
with 5 µm cisplatin treatment for another 24 h [4]. Repression of
LMO4 was veriﬁed by immunoblotting with anti-LMO4.
2.8. Transient overexpression of LMO4
Mammalian expression vector pRK5 (catalog no. 22964, Addgene,
Cambridge, MA) was used for the overexpression of LMO4, following
the manufacturer's protocol. UBOC1 cells were transfected with HA-
tagged LMO4 using lipofectamine reagent (Invitrogen, Carlsbad, CA) at
50–60% conﬂuence and cultured for 48 h. Transfection of the plasmid
DNA was veriﬁed by immunoblotting with HA-Tag (6E2) mouse
antibody (Cell Signaling, Danvers, MA) and overexpression of LMO4
was veriﬁed by immunoblotting with anti-LMO4 [35].
2.9. Cell viability count
The viability of the cells was determined by counting the number of
cells that were not stained with trypan blue (live cell count) relative to
the total number of cells (total cell count), using a hemocytometer.
Fig. 1. Cisplatin-induced increase in nitrotyrosine is attenuated by SRI110. A) Increased levels of nitrotyrosine as well as condensed nuclei (white arrows) were detected in
UBOC1 cells treated with 10 µm cisplatin. Co-treatment with 50 µm SRI110 attenuated the cisplatin-induced increase in nitrotyrosine. Red staining indicates immunoreactivity to anti-
nitrotyrosine, blue indicates nuclear staining with DAPI, while green indicates actin staining with phalloidin. The images are representative of four biological replicates. Scale bar, 20 µm.
(B) The mean pixel intensities for nitrotyrosine immunostaining was signiﬁcantly higher in cisplatin treated cells (****P < 0.0001), which was attenuated by SRI110 co-treatment (***P
< 0.001). The results are expressed as mean ± standard deviation, n=4. (C) Immunostaining (violet) with anti-myosin VIIa indicated the diﬀerentiated state of UBOC1 cells. The image is
representative of three biological replicates. Scale bar, 20 µm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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2.10. MTT assay
UBOC1 cells were treated with 10 μl of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml in PBS)
and incubated at 37 °C in 5% CO2 for 4 h, following the manufacturer's
protocol (catalog no. CT02, EMD Millipore Corporation, Temecula,
CA). The formazan crystals, formed by the reduction of MTT by active
mitochondria present in the viable cells, were dissolved by adding
100 μl of 0.04 N HCl in isopropanol. The absorbance was measured at
570 nm using a microplate reader, with a reference wavelength of
630 nm.
2.11. Caspase 3 ﬂuorescence assay
Activation of caspase 3 was assayed as a biomarker of apoptosis,
using a Fluorescein Active Caspase 3 Staining Kit (catalog no. ab39383,
Abcam, Cambridge, MA). UBOC1 cells were plated in six-well culture
plates and treated with cisplatin or SRI110 or both for 24 h. The cells
were re-suspended and treated with FITC-DEVD-FMK reagent follow-
ing the manufacturer's protocol. Fluorescence generated by the reac-
tion between a caspase 3 substrate (FITC-DEVD-FMK) and active
caspase 3, upon cleavage, was analyzed by ﬂow cytometry. Z-VAD-FMK
reagent, a caspase inhibitor, was used for the negative controls.
2.12. Auditory brainstem response
Hearing thresholds were measured after anesthetizing the animals
with isoﬂurane (4% induction, 1.5% maintenance with 1 L/min O2).
ABR was recorded using subcutaneous diﬀerential active needle
electrodes with sound stimuli of 1-ms tone bursts (4, 8, 16, 24, or
32 kHz) or 25-µs clicks, generated using Tucker-Davis Technologies
BioSigRZ software and TDT System3 hardware (TDT, Alachua, FL).
The stimuli were presented to the external auditory meatus and two
hundred stimulus presentations, delivered at 21/s, was averaged to
obtain the waveform of the brainstem response. The lowest intensity of
stimulation at which a waveform with an identiﬁable peak was detected
was considered as the hearing threshold [12].
2.13. Data analysis
All data were statistically analyzed using two-tailed unpaired t-test
and P value of < 0.05 was considered signiﬁcant. GraphPad Prism 6
software (GraphPad, La Jolla, CA) was used for statistical analysis and
the results are expressed as mean ± standard deviation.
3. Results
3.1. Cisplatin-induced protein nitration was inhibited by treatment
with PNDC
We reported that cisplatin treatment increased the nitration of
proteins in rat cochlea as well as UBOC1 cell cultures [4,35]. In order to
determine whether treatment with PNDC could prevent cisplatin-
induced protein nitration UBOC1 cells were treated with 50 µm of
SRI110 1 h before 10 µm cisplatin treatment. After 24 h, the cells were
probed with anti-nitrotyrosine and the immunoreactivity with nitro-
tyrosine was visualized by confocal microscopy. Consistent with our
previous studies cisplatin signiﬁcantly increased the levels of nitrotyr-
osine and induced apoptosis, which was evident from the condensed
nuclei. Co-treatment with SRI110 attenuated the cisplatin-induced
increase in nitrotyrosine as well as the apoptotic changes observed in
the nuclei (Fig. 1). This suggested that PNDCs inhibit the cisplatin-
induced nitrative stress in the inner ear cells.
Fig. 2. SRI110 attenuates cisplatin-induced downregulation of LMO4 in a dose-dependent manner. A) Immunoblots with anti-LMO4 indicated that cisplatin treatment
signiﬁcantly decreased the protein levels of LMO4. Co-treatment with 25 µm of SRI110 did not alter the cisplatin-induced decrease in LMO4 levels. However, co-treatment with 50 µm
of SRI110 signiﬁcantly attenuated the cisplatin-induced decrease in LMO4, suggesting a dose-dependent response to SRI110 treatment. The results are expressed as mean ± standard
deviation, n=4. ** P < 0.01, relative to control. B) Scatter plots indicated that in control cells LMO4 (orange) is heavily expressed while cisplatin treatment induced an increase in
nitrotyrosine (red) levels. SRI110 co-treatment attenuated the cisplatin-induced decrease in LMO4 levels. The plots are representative of biological replicates. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.2. Inhibition of nitrative stress attenuated cisplatin-induced
downregulation of LMO4 in a dose-dependent manner
Our previous studies indicated that in addition to increased
nitration of cochlear proteins, cisplatin treatment decreased the levels
of LMO4 in the cochlea. We hypothesized that cisplatin-induced
nitrative stress leads to a decrease in LMO4 protein levels because
nitrated proteins are potential candidates for proteasomal degradation
[28,31]. To test whether scavenging of peroxynitrite could attenuate
the cisplatin-induced downregulation of LMO4, we treated UBOC1
cells with two diﬀerent doses of SRI110 (25 or 50 µm), 1 h before
10 µm cisplatin treatment. After 24 h, the proteins were extracted from
the cells, separated on a gel, transferred to a polyvinylidene ﬂuoride
membrane, and probed with anti-LMO4. The detected LMO4 protein
bands were quantiﬁed by normalizing with that of actin. Cisplatin
treatment decreased the levels of LMO4, which was at 58%, relative to
controls, while the levels of LMO4 after co-treatment with 25 or 50 µm
of SRI110 was at 70% and 88%, respectively (Fig. 2). The observations
were supported by scatter plots generated through immunocytochem-
ical analysis, which indicated that SRI110 co-treatment (50 µm)
attenuated not only the cisplatin-induced increase in nitrotyrosine
levels but also the decrease in LMO4 levels. These ﬁndings indicated
that scavenging of peroxynitrite attenuates cisplatin-induced down-
regulation of LMO4 in a dose-dependent manner and suggested that
cisplatin-induced nitrative stress is partly responsible for the decrease
in the levels of LMO4.
3.3. Downregulation of LMO4 exacerbated cisplatin-induced
cytotoxicity
To determine whether the downregulation of LMO4 could promote
the ototoxic eﬀects of cisplatin, we silenced LMO4 expression in
UBOC1 cells using SiRNAs and assessed the cisplatin-induced cytotoxic
eﬀects using cell counts. UBOC1 cells were transfected with 4 diﬀerent
LMO4 SiRNAs and the decrease in LMO4 protein levels were analyzed
by immunoblotting with anti-LMO4. Actin was used to normalize the
expression of LMO4. Repression of LMO4 with SiRNAs resulted in a
40% decrease in the protein levels of LMO4. Treatment of wild-type
cells with cisplatin induced only 18% decrease in cell viability.
However, treatment of the LMO4 deﬁcient cells with 5 µm cisplatin
exacerbated the cisplatin-induced cytotoxicity, which was indicated by
46% decrease in the cell counts (Fig. 3). This was also supported by the
increase in the number of condensed nuclei in LMO4 deﬁcient cells
relative to wild-type cells treated with cisplatin. These ﬁndings
suggested that in the absence of LMO4 the susceptibility of the inner
ear cells to cisplatin-induced toxicity is signiﬁcantly enhanced and is
consistent with other reports, which indicate repression of LMO4
promotes apoptosis [37]. The viability of UBOC1 cells treated with
scrambled RNA was similar to that of the control cells.
3.4. Overexpression of LMO4 attenuated cisplatin-induced
cytotoxicity
Because LMO4 regulates cellular apoptosis and downregulation of
LMO4 facilitated cisplatin-induced cytotoxicity we hypothesized that
overexpression of LMO4 will prevent the cytotoxic eﬀects induced by
cisplatin. To test this hypothesis, we transiently overexpressed LMO4
in UBOC1 cells and evaluated the cytotoxic eﬀects of cisplatin using
MTT assay. Cisplatin treatment (5 µm) signiﬁcantly decreased the cell
viability by 25% in wild-type UBOC1 cells while overexpression of
LMO4 not only prevented the cisplatin-induced cell death but sig-
niﬁcantly increased the cell viability by 38% (Fig. 4). This suggested
that at normal or higher levels LMO4 plays a protective role and
prevents cisplatin-induced cell death. Overexpression of LMO4 was
veriﬁed by immunoblotting with anti-LMO4, which was normalized by
immunoblotting with anti-actin.
3.5. Inhibition of nitrative stress attenuated cisplatin-induced
apoptosis
Our results indicated that the expression levels of LMO4 are a
critical determinant of cisplatin-induced cytotoxicity and inhibition of
nitrative stress attenuated cisplatin-induced downregulation of LMO4.
Therefore, scavenging of peroxynitrite is also expected to attenuate
cisplatin-induced cytotoxicity, which primarily occurs through apopto-
sis. To test this hypothesis we treated UBOC1 cells with 50 µm of
SRI110 and assessed the expression of active caspase 3, a biomarker of
apoptosis, by ﬂow cytometry. Cisplatin treatment (10 µm) induced a
signiﬁcant increase in active caspase 3 levels in UBOC1 cells (p >
0.001), when compared to the controls. Co-treatment with SRI110
attenuated the cisplatin-induced increase in caspase levels (p > 0.001).
In the cells that were treated with only SRI110 the caspase activity was
similar to that of the controls (Fig. 5). This suggested that inhibition of
nitrative stress prevents cisplatin-induced apoptosis in the inner ear
cells.
3.6. Inhibition of nitrative stress mitigated cisplatin-induced hearing
loss
Though the cytotoxic eﬀects of cisplatin in this inner ear cell culture
model were mitigated by treatment with PNDC, this interventional
approach may not be relevant to cisplatin-induced ototoxicity unless
the eﬃcacy is veriﬁed in a murine model. Therefore, we used CBAJ
mice, which are good models for studying cisplatin ototoxicity [41], and
treated them with 3 mg/kg dose of cisplatin daily for ﬁve consecutive
days. Hearing was assessed on the eighth day by testing ABRs (Fig. 6A
and B). Cisplatin treatment induced a 10–15 dB shift in the hearing
thresholds while co-treatment of SRI110 at 10 mg/kg dose daily, by
oral administration for ﬁve consecutive days, attenuated the cisplatin-
induced hearing loss (p > 0.05, at 8 kHz). In addition, SRI110 co-
treatment signiﬁcantly attenuated the cisplatin-induced weight loss
(Fig. 6C). This suggested that PNDCs could emerge as a promising
interventional approach to prevent cisplatin ototoxicity.
4. Discussion
Nitrated proteins play an important role in mediating cell death
responses, and their signaling has been eﬀectively targeted to inhibit
cell death in several experimental models [42–44]. However, the
nitrative stress mechanism underlying cisplatin-induced ototoxicity
remains only partially understood. In previous studies, we reported
that cisplatin treatment leads to the nitration and downregulation of
cochlear LMO4 [4,35]. Here, we provide evidence that selective
inhibition of nitrative stress by SRI110 attenuates cisplatin-induced
downregulation of LMO4 and apoptosis in cell cultures of the auditory
sensory epithelium. In addition, co-treatment of SRI110 mitigated
cisplatin-induced hearing loss in CBA/J mice indicating the functional
signiﬁcance of nitrative stress in cisplatin ototoxicity. Furthermore,
transient overexpression of LMO4 in cell cultures prevented cisplatin-
induced cytotoxicity while repression of LMO4 worsened the toxic
eﬀects of cisplatin. Together, these ﬁndings suggest that cisplatin-
induced nitrative stress and downregulation of LMO4 plays a critical
role in facilitating cisplatin-induced ototoxicity.
In this study, UBOC1 cell cultures and CBA/J mice were used to
determine the contribution of LMO4 and nitrative stress to cisplatin
ototoxicity. These are good experimental models for studying ototoxi-
city and have been employed by other researchers to investigate the
molecular mechanisms underlying cisplatin-induced ototoxicity [5,41].
We used fully diﬀerentiated UBOC1 cells in all our experiments, which
were veriﬁed by testing the expression of myosin VIIa, a biomarker of
hair cells. In animal studies, only male mice were used in order to avoid
potential interference in LMO4 signaling from any changes in the sex
hormones, particularly, estrogen because LMO4 is known to bind with
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estrogen receptors and repress its transactivation activities [45]. The
CBA/J mice were administered cisplatin by following a 5-day treatment
regimen, in order to mimic the clinical use of cisplatin, and their
hearing loss was assessed by recording auditory brainstem responses
before and after cisplatin treatment. Pharmaceutical grade cisplatin
was used in the in-vivo studies while SRI110 was synthesized in-house
[19]. The eﬀect of the drug treatment was analyzed by immunoblotting
and immunocytochemistry and the speciﬁcity of the immunoreaction
with nitrotyrosine and LMO4 antibodies were veriﬁed as described in
previous publications [4,35]. The eﬃciency of transient overexpression
as well as repression of LMO4 in UBOC1 cell cultures was veriﬁed by
immunoblots with anti-LMO4.
The ototoxic side-eﬀects of cisplatin are predominantly mediated by
oxidative stress [3,9] and protein nitration is an important sequela of
oxidative stress. In agreement, cisplatin treatment increased the levels
of nitrotyrosine in UBOC1 cells. In addition, it also increased the
expression of active caspase 3, indicating cisplatin-induced apoptosis
in these cell cultures. Because protein nitration can cause vital changes
in biological function depending on the functional characteristics of the
nitrated protein, identiﬁcation of the nitrated protein(s) is essential to
understand its functional signiﬁcance. We previously identiﬁed cispla-
tin-induced nitration of cochlear LMO4, in Wistar rats, by immuno-
precipitation followed by Matrix Assisted Laser Desorption/
Ionization–Time Of Flight mass spectrometry [4], and veriﬁed the
co-localization of nitrotyrosine and LMO4 in UBOC1 cells [35]. In
addition to nitration of LMO4, cisplatin treatment decreased the levels
of LMO4, which is consistent with reports that indicate nitrated
proteins are potential targets for proteasomal degradation [31,43,46].
However, the functional implications of decreased levels of cochlear
LMO4 in cisplatin-induced ototoxicity are not fully known.
LMO4 has the potential to mediate cytotoxicity, as it controls
pathways regulating cell survival and cell death by modulating the
Fig. 3. Silencing of LMO4 exacerbates cisplatin-induced cell death. (A) LMO4 was repressed in UBOC1 cells by using siRNAs. Treatment of LMO4 deﬁcient cells with 5 µm
cisplatin signiﬁcantly decreased the number of viable cells when compared to cisplatin-treated wild-type UBOC1 cells. The results are expressed as mean ± standard deviation, n=3.
****P < 0.0001. (B) Repression of LMO4 by siRNAs was quantiﬁed by immunoblotting with anti-LMO4 and normalized with that of actin. Treatment with SiRNAs induced a 40%
decrease in the levels of LMO4 (n=3, *P < 0.05). (C) Nuclear staining with DAPI indicated that the number of condensed nuclei (white arrows) is much higher in the LMO4 deﬁcient cells
than in the wild-type cells, after cisplatin treatment. The images are representative of four biological replicates. Scale bar, 20 µm.
Fig. 4. Overexpression of LMO4 prevents cisplatin-induced decrease in cell viability. (A) MTT assay indicated that cisplatin treatment decreased the viability of UBOC1
cells. Overexpression of LMO4 attenuated the cisplatin-induced decrease in cell viability. The results are expressed as mean ± standard deviation, n=3. ***P < 0.001, ****P < 0.0001. (B)
The eﬃciency of transfection was indicated by immunoblots, which showed a 117% increase in the expression of LMO4 in overexpressed cells, but not in control cells. LMO4 expression
was normalized with that of actin (n=3, *P < 0.05).
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formation of transcriptional complexes that repress or promote tran-
scription of pertinent genes [20,22,23,45,47]. Our recent studies
indicated that cisplatin-induced nitration and downregulation of
LMO4 occurs not only in the auditory cells (UBOC1), but also in the
renal (HK2), and neuronal (SH-SY5Y) cells [35]. To clarify the
functional signiﬁcance of downregulation of LMO4 in cisplatin-induced
cytotoxicity we overexpressed LMO4 in UBOC1 cells using pRK5
vectors. The transient overexpression of LMO4 not only prevented
cisplatin-induced cytotoxicity at this dose but also signiﬁcantly in-
creased cell viability indicating a potential anti-apoptotic role of LMO4.
Moreover, silencing of LMO4 with siRNAs exacerbated the cisplatin-
induced cytotoxicity in UBOC1 cells, which is consistent with other
reports that indicated repression of LMO4 promotes apoptosis [37].
Collectively, these results suggested a direct link between LMO4
protein levels and cellular apoptosis in cisplatin-mediated cytotoxicity.
In order to decipher the contribution of nitrative stress to cisplatin-
induced decrease in LMO4 levels and thus to ototoxicity we used
SRI110 to scavenge cisplatin-induced generation of peroxynitrite.
SRI110 is a manganese (III) bishydroxyphenyldipyrromethene-based
peroxynitrite decomposition catalyst that was designed to selectively
target peroxynitrite [19]. Targeting the nitrative stress pathway that
facilitates the toxic side-eﬀects of cisplatin appears to be an attractive
strategy for intervention because it minimizes potential interference
with the anti-cancer activity of cisplatin, which is primarily mediated
by the formation of DNA adducts. Related metalloporphyrins have
been reported to prevent cisplatin-induced protein nitration and
nephrotoxicity [48]. SRI110 has several advantages as a potential
otoprotective compound because of the following reasons. First, it did
not interfere with the anticancer activities of paclitaxel. Second, it
spares the superoxide radical, which has other signaling roles particu-
larly in learning and memory. Third, its oral bioavailability enables it to
be easily and continuously used throughout cancer treatment. In this
study, inhibition of nitrative stress by SRI110 decreased the cisplatin-
induced increase in nitrotyrosine and caspase 3 levels, attenuated the
cisplatin-induced downregulation of LMO4 in UBOC1 cells in a dose
dependent manner, and mitigated cisplatin-induced hearing loss and
weight loss in CBA/J mice.
5. Conclusions
Our results provide compelling evidence to suggest that PNDCs
could be eﬀectively employed to mitigate nitrative stress-induced
otopathology and they could be administered orally to selectively target
peroxynitrite, which is not known to have any beneﬁcial roles. These
ﬁndings are signiﬁcant and may have broader implications because
nitrative stress is emerging as an important factor not only in cisplatin-
induced hearing loss, but also in other types of acquired hearing loss
such as noise-induced and age-related hearing loss [13,17].
Furthermore, by deﬁning the critical link between cisplatin-induced
hearing loss, nitrative stress, and downregulation of LMO4, which was
also detected in cisplatin-induced damage to renal and neuronal cells
[35], this study provides a strong foundation for the identiﬁcation and
development of novel targets for therapeutic intervention. These out-
comes, in turn, will increase the clinical utility of this crucial life-saving
drug and improve the quality of life of the cancer survivors treated with
cisplatin.
Fig. 5. Inhibition of nitrative stress attenuates cisplatin-induced apoptosis. The illustrations indicate the changes in the expression of active caspase 3 in UBOC1 cells,
detected by ﬂow cytometry analysis. Cisplatin treatment induced an increase in active caspase 3 levels while SRI110 co-treatment attenuated it. Treatment with SRI110 alone did not
alter the active caspase 3 levels. The images are representative of three biological replicates. The results are expressed as mean ± standard deviation, n=3. ***P < 0.001.
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